← Back to Search

Thiazolidinedione

Pioglitazone 15mg Dose for Breast Cancer

Phase 2

Recruiting

Led By Kristin H Lupinacci, DO

Research Sponsored by West Virginia University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 6 weeks

Awards & highlights

Study Summary

This trial is testing if pioglitazone can help treat muscle fatigue in breast cancer patients.

Eligible Conditions

Breast Cancer
Muscle Fatigue

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 6 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 6 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Muscle Gene Expression

Secondary outcome measures

Body Weight

Muscle Fatigue

Trial Design

3Treatment groups

Active Control

Group I: Pioglitazone 15mg DoseActive Control1 Intervention

Subjects will be given PIO 15mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.

Group II: Pioglitazone 30mg DoseActive Control1 Intervention

Subjects will be given PIO 30mg once daily, based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.

Group III: No DrugActive Control1 Intervention

Subjects will be assigned to a no drug control group based on the randomization lists prepared by the WVUCI Biostatistics Core. This is a 1:1:1 randomization (10 in each group) without any planned stratification.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

West Virginia UniversityLead Sponsor

176 Previous Clinical Trials

60,184 Total Patients Enrolled

3 Trials studying Breast Cancer

39 Patients Enrolled for Breast Cancer

Kristin H Lupinacci, DOPrincipal InvestigatorWest Virginia University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

In what type of medical circumstance is Pioglitazone 30mg Dose typically prescribed?

"Pioglitazone 30mg Dose is a viable therapeutic option for managing diabetes, diabetic neuralgia, and dietary requirements."

Answered by AI

Has the Food and Drug Administration sanctioned a dosage of Pioglitazone at 30mg?

"Our team at Power concluded that Pioglitazone 30mg Dose had a safety rating of 2 since this is only in Phase 2, meaning there is some evidence to suggest it may be safe but no data affirming its efficacy."

Answered by AI

Has there been any prior research conducted regarding the efficacy of a thirty milligram dosage of Pioglitazone?

"Currently, 31 clinical trials are being conducted to analyze the efficiency of a 30mg dose of Pioglitazone. Of those studies, 4 are in Phase 3 and they span 69 different locations with the majority located in Lausanne, Vaud."

Answered by AI

Is this experiment actively seeking participants?

"Indeed, the listing on clinicaltrials.gov specifies that recruitment for this medical trial is still ongoing. The study was posted online in December 2021 and last revised in July 2022, with a total of 30 patients required from 1 centre."

Answered by AI

How many patients have enrolled in this experiment thus far?

"Affirmative. According to the records hosted on clinicaltrials.gov, recruitment for this medical research is still active since its original posting date of December 23rd 2021 and last update July 11th 2022. 30 participants are being sought from one site for enrollment in the project."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Pioglitazone Therapy Targeting Fatigue in Breast Cancer

Kristin Lupinacci 2021. "Pioglitazone Therapy Targeting Fatigue in Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05013255.